September 8, 2023 Release Highlights Copied

09/08/20232023 VBCRelease note

Practice Insights is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS) and Enhancing Oncology Model (EOM).

MIPS Quality Measures Dashboard

Promoting Interoperability Measure Specification Refinements

The dashboard has been updated to reflect scoring changes for the below measures:

Measure Update
Provide Patient Access to Electronic Health Records When submitting this measure at the end of the year, the maximum number of points received will now be 25 points, not 40 points.
Closing the Referral Loops by Sending Health Information When submitting this measure at the end of the year, the maximum number of points received will now be 15 points, not 20 points.
Closing the Referral Loops by Receiving & Reconciling Health Information When submitting this measure at the end of the year, the maximum number of points received will now be 15 points, not 20 points.

Quality Measures Technical Refinements

The dashboard has also been updated to reflect the below refinement(s) for:

Measure Update Practice Impact
PIMSH 15: Antiemetic Therapy for Low-and-Minimal-Emetic Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure)
  • While the measure was coded as expected an issue was identified with how the measure was displaying patients in the Minimal category. This release addresses that issue.
  • Technical refinement to ensure the patient is attributed to the clinician with the qualifying E/M visit.
  • Cyclophosphamide was included up to >=1500 but now will be included with dosage >1500.
  • Technical refinement to better capture new or refilled prescription orders of an antiemetic within 89 days prior to cycle 1 day 1 of the therapy.
  • Medications on the Current Medications list will be captured when there is an active order on the medication list 90 days prior to cycle 1 day 1 of therapy.
 Practices will notice an increase in the Numerator and Denominator.
PIMSH 16: Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center
  • While the measure was coded as expected an issue was identified with how the measure was displaying patients in the Minimal category. This release addresses that issue.
  • Technical refinement to ensure the patient is attributed to the clinician with the qualifying E/M visit.
  • Technical refinement to better capture new or refilled prescription orders of an antiemetic within 89 days prior to cycle 1 day 1 of the therapy.
  • Medications on the Current Medications list will be captured when there is an active order on the medication list 90 days prior to cycle 1 day 1 of therapy.
 Practices will notice an increase in the Numerator and Denominator.

VBC Navigation Summary Dashboard

We updated the VBC Navigation Summary dashboard to provide you with more accurate and comprehensive insights into VBC Care Plan information sourced from iKnowMedSM Generation 2. These updates aim to streamline your workflow and empower you with crucial hospice-related data.

Here’s what you can expect from the newly added columns:

  1. Referral to Hospice: This column will display the status of patients’ referral to hospice care, offering a clear overview of whether patients have been referred.
  2. Referral to Hospice Date: Gain deeper insights into the timing of hospice referrals with this date field.
  3. Enrolled in Hospice: Keep track of whether patients are actively enrolled in hospice care.
  4. Enrolled in Hospice Date: Understand the exact enrollment dates for patients in hospice care.

All this essential information will be seamlessly populated from the VBC Care Plan, ensuring that your dashboard remains up-to-date and accurate. These enhancements are designed to optimize your view of patients participating in quality payment programs.

Status of Dashboard Updates for 2023

CMS releases updates to the quality measure specifications annually for the MIPS program and bi-annually for the OCM program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. McKesson will continue to notify practices once measures have been updated based on the current 2023 requirements. The measures listed below either have no 2023 update required or have been updated.

Measure Description

MIPS Quality Measures Dashboard
#047 Advance Care Plan

#104

 Adjuvant Hormonal Therapy for High-Risk or Very High-Risk Prostate Cancer

#130

 Current Medications Documentation
#134 Preventive Care Screening: Screening for Depression and Follow-Up Plan
#143 Pain Intensity Quantified
#144 Pain Care Plan
#226 Tobacco Screening and Cessation

#236

Controlling High Blood Pressure
#374 Closing the Referral Loop
#451 RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy
#452 Percentage of Adult Patients (aged 18 or older) with Metastatic Colorectal Cancer and RAS (KRAS & NRAS) Gene Mutation Spared Treatment with Anti-EGFR Monoclonal Antibodies

#457

Patients Admitted to Hospice for < 3 Days

PIMSH#1

Advance Care Planning in Stage 4 Disease
PIMSH#2 Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure)
PIMSH#4 Patient-Reported Pain Improvement

PIMSH#8

Mutation Testing for Lung Cancer
PIMSH#9 Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure)
PIMSH#10 Hepatitis B Serology Testing for Prophylactic Treatment Prior to Receiving Anti CD20 Targeting Drugs

PIMSH#15

 Antiemetic Therapy for Low-and-Minimal-Emetic Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure)

PIMSH#16

 Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center